BB Biotech

Last updated
BB Biotech AG
Type Aktiengesellschaft
SIX:  BION [1]
FWB:  BBZA [2]
Euronext:  BIO.MI [3]
Industry Investments
Founded9 November 1993 (9 November 1993) [4]
Headquarters Schaffhausen, Switzerland [5]
Key people
Erich Hunziker
(Chairman) [6]
ProductsInvestment in biotechnology companies
Increase2.svg CHF - 357 million
(2022) [7]
Total assets Decrease2.svgCHF 2.578 billion
(2022) [7]
Website www.bbbiotech.ch

BB Biotech AG is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and from 2000 to 2023 [8] on the Italian Borsa Italiana. [9] The company invests mainly in the United States and Western Europe [10] and is managed by Bellevue Asset Management, a division of Bellevue Group [11] which accounts for approximately 40% of the Group's assets under management. [12]

Contents

Investment activities

As a closed-end fund, with its principal activity of specialised investments in companies operating in biotech sector, [13] [14] BB Biotech is the oldest-established [12] and largest entity of its kind. [11] [15]

BB Biotech's investment strategy covers a long-term time horizon and targets biotechnology firms with either already established products in the marketplace [16] or promising drug candidates in advanced development stages. [17]

Aiming exclusively at human therapeutic companies, the company rules out med-tech, diagnostics and other similar activities [12] and further concentrates on firms developing therapeutic products [13] involving cell, gene and particularly RNA-based technologies. [12]

In contrast to other biotech specialists or hedge funds, Biotech as a long-only investor, does not need to rely on financial instruments to reduce individual stock or market risk. [12]

Primary geographic focus lies on small-to-mid-cap biotech companies headquartered in Western Europe [18] or the United States market [19] as a domicile for the majority of the world’s biotechnology companies, [20] or those listed on Nasdaq. [12]

While benchmarked against the Nasdaq Biotech index (in CHF), [21] [22] the company uses a bottom-up approach [17] based on the fundamental analysis. [12] Its portfolio comprises around 35 companies [14] and includes holdings in Ionis Pharmaceuticals, Moderna, Neurocrine Biosciences, Argenx, Incyte, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Arvinas, Fate Therapeutics, Agios Pharmaceuticals and Halozyme Therapeutics. [23]

Over the decade leading to 2020, it consistently met its own aim to deliver 15% of annual growth in capital [12] including a 5% dividend per year. [11]

History

BB Biotech AG mainly invests in the fields of oncology, cardiovascular diseases, metabolic diseases, infectious diseases and autoimmune diseases. [14]

Core investments

The six core investments in the BB Biotech portfolio as of June 30, 2023 included Ionis Pharmaceuticals (13.3%), Argenx (11.7%), Vertex (10.4%), Neurocrine Biosciences (8.5%), Intra-Cellular Therapies  (6.9%) and Moderna (6.2%). [24]

Company figures

Company figures are as follows: [25] [26]

(figures in millions CHF)20222021202020192018201720162015
Profit/(Loss) (356) [27] (405)691 [7] [28] 677(471)687(802)653
Net asset value 2'6863'2833'888 [28] 3'3932'8853'5393'0033'978
Market capitalization 3'0584’2744108 [29] [28] 3'6703'2353'5763'0533'463

Related Research Articles

<span class="mw-page-title-main">London Stock Exchange</span> Stock exchange in the City of London

London Stock Exchange (LSE) is a stock exchange in the City of London, England, United Kingdom. As of August 2023, the total market value of all companies trading on the LSE stood at $3.18 trillion. Its current premises are situated in Paternoster Square close to St Paul's Cathedral in the City of London. Since 2007, it has been part of the London Stock Exchange Group. The LSE was the most-valued stock exchange in Europe from 2003 when records began until Autumn 2022, when the Paris exchange overtook it. According to the 2020 Office for National Statistics report, approximately 12% of UK-resident individuals reported having investments in stocks and shares. According to the 2020 Financial Conduct Authority (FCA) report, approximately 15% of UK adults reported having investments in stocks and shares.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

<span class="mw-page-title-main">Ernesto Bertarelli</span> Swiss-Italian billionaire

Ernesto Silvio Maurizio Bertarelli is an Italian-born Swiss billionaire businessman and philanthropist.

<span class="mw-page-title-main">Borsa Italiana</span> Italian stock exchange

Borsa Italiana, based in Milan, is the Italian stock exchange. It manages and organises domestic market, regulating procedures for admission and listing of companies and intermediaries and supervising disclosures for listed companies.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

<span class="mw-page-title-main">Keytrade Bank</span> Financial services company based in Belgium

Keytrade Bank is a financial services company based in Belgium with a subsidiary in Luxembourg.

<span class="mw-page-title-main">London Stock Exchange Group</span> British financial services company

London Stock Exchange Group plc (LSEG) is a United Kingdom-based stock exchange and financial information company headquartered in the City of London, England. It owns the London Stock Exchange, Refinitiv, LSEG Technology, FTSE Russell, and majority stakes in LCH and Tradeweb.

<span class="mw-page-title-main">Evotec</span> German biopharmaceutical company

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.

David Abraham Blech is an American businessman, investor, and venture capitalist. He is one of the financial pioneers of the biotech industry and was once known as the "King of Biotech".

<span class="mw-page-title-main">CureVac</span> German bio-pharmaceutical company

CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac has approximately 375 employees since May 2018.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenix Inc., the company went public in 1992. Initially focused on developing its own drugs, a period of turbulence in the early 2000s culminated in its CEO being ejected by the shareholders and provoked a change in focus to the acquisition of existing drugs and forming partnerships to develop them further.

<span class="mw-page-title-main">Ionis Pharmaceuticals</span> Biotechnology company

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.

David Ebsworth is non-executive chairman at Verona Pharma Plc. His career spans over 35 years in the global pharmaceutical industry, during which he was Global Head of Pharmaceuticals at Bayer AG and CEO of a number of companies, including ViforPharma and Galenica. He is also an advisor to a variety of CEOs at public and private organisations.

<span class="mw-page-title-main">ProQR</span> Dutch biotechnology company

ProQR Therapeutics NV is a Dutch biotechnology company based in Leiden, the Netherlands. In addition to its headquarters in Leiden, the company also has a presence in Cambridge, Massachusetts. The company was funded in 2012 by chief executive officer (CEO) Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer.

<span class="mw-page-title-main">Akshay Naheta</span> Indian-born British business executive

Akshay Naheta is an Indian-born British business executive. He is the Founder & CEO of Distributed Technologies Research (DTR), a decentralized finance startup focusing on stablecoin technology and other linked services.

<span class="mw-page-title-main">Bellevue Group</span> Swiss investment management corporation

Bellevue Group AG, headquartered in Küsnacht, is a listed investment management corporation from Switzerland. Bellevue Group consists of the subsidiaries Bellevue Asset Management, Bellevue Private Markets and StarCapital. It has 9,6 billion Swiss francs Assets Under Management Around 80% of clients assets are in healthcare investments. Bellevue Group is also active in alternative investments and private equity, including co-investments in private domestic small and medium-sized enterprises. In this business area, client assets under management were 1.0 billion francs as of mid-2021.

References

  1. ↑ "BION.S - BB BIOTECH AG All Listings | Reuters". www.reuters.comundefined. Retrieved 20 October 2021.
  2. ↑ "BB Biotech AG Equity | A0NFN3 | CH0038389992 | Share Price". www.boerse-frankfurt.de. Retrieved 20 October 2021.
  3. ↑ "Bb Biotech Stocks Quotes: Company Profile - Borsa Italiana". www.borsaitaliana.it. Retrieved 20 October 2021.
  4. ↑ AG, DV Bern. "BB Biotech AG". Official Companies Register of the Canton of Schaffhausen (in German). Retrieved 20 October 2021.
  5. ↑ "BB Biotech AG. Zentraler Firmenindex". www.zefix.ch (in German). Retrieved 20 October 2021.
  6. ↑ "BB BIOTECH - About us. Board of Directors". www.bbbiotech.ch. Retrieved 20 October 2021.
  7. 1 2 3 "BB Biotech AG, BION:SWX financials - FT.com". markets.ft.com. Retrieved 31 August 2023.
  8. ↑ "Delisting from Borsa Italiana". BB Biotech. 2023-08-21. Retrieved 2023-08-31.
  9. ↑ "BB Biotech". Borsa Italiana. Retrieved 3 June 2020.
  10. ↑ "BB Biotech AG". Bloomberg. Retrieved 8 January 2022.
  11. 1 2 3 QuotedData by Marten & Co (11 February 2021). "BB Biotech AG. A leading biotech investor" (PDF). Retrieved 7 November 2021.
  12. 1 2 3 4 5 6 7 8 "BB Biotech AG - A leading biotech investor". QuotedData. 11 February 2021. Retrieved 7 November 2021.
  13. 1 2 "BB Analysis - BB Biotech AG Fund - Bloomberg Markets". www.bloomberg.com. Bloomberg . Retrieved 8 January 2022.
  14. 1 2 3 "BB Biotech AG 0JYO-GB:London Stock Exchange". CNBC . Retrieved 2 June 2022.
  15. ↑ "BB Biotech AG Share Price | BIOEE | Morningstar" . Retrieved 2 June 2022.
  16. ↑ "BB Biotech AG Bearer Shares (BBAGF)". NASDAQ, Inc. Retrieved 2 June 2022.
  17. 1 2 Sarah Godfrey, Mel Jenner. "BB Biotech SW: BION". Edison Investment Research Limited. Retrieved 2 June 2022.
  18. ↑ "DGAP-News: BB BIOTECH AG: Disruptive technologies are changing an entire industry". www.finanzen.ch. 24 May 2022. Retrieved 2 June 2022.
  19. ↑ "BB Biotech AG, BION:SWX profile - FT.com". markets.ft.com. Retrieved 7 November 2021.
  20. ↑ Sarah Godfrey, Mel Jenner (1 March 2021). "BB Biotech - Looking for innovation beyond the pandemic. Review". Edison Investment Research Limited. Retrieved 2 June 2022.
  21. ↑ Kadhim Shubber (24 August 2015). "US biotech tumbles into bear market". Financial Times . Retrieved 2 June 2022.
  22. ↑ Evans, Richard (9 December 2021). "Questor: biotech has been shunned this year despite the vaccines triumph – so buy these trusts". The Telegraph . Retrieved 2 June 2022.
  23. ↑ "BB Biotech - Our holdings". www.bbbiotech.ch. BB Biotech AG. Retrieved 8 January 2022.
  24. ↑ "Portfolio". BB Biotech. Retrieved 2023-08-31.
  25. ↑ finanzen.net Retrieved 1st of January 2016.
  26. ↑ "BB Biotech - Facts & Figures". BB Biotech. 11 March 2020. Archived from the original on 2016-03-21.
  27. ↑ "Annual Report 2022". BB Biotech. Retrieved 2023-08-31.
  28. 1 2 3 "BB BIOTECH -Facts & Figures". www.bbbiotech.ch. Retrieved 20 October 2021.
  29. ↑ "BB Biotech - Annual Report 2020". BB Biotech - Annual Report 2020. Retrieved 20 October 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.